June 6, 2024 – Bloomington, MN – Leading provider of solutions for managing high-cost therapies, Emerging Therapy Solutions® (ETS), promotes Ashley Hume to President. This strategic move strengthens ETS’s focus on deepening and expanding services to meet evolving client needs in the rapidly growing cell and gene therapy market.
Hume’s proven track record positions her perfectly to lead ETS into the future. As Chief Commercial Officer, she spearheaded strategic partnerships client relationships, product innovation, and team development. These efforts have ensured continued best-in-class service delivery for ETS clients and rapid growth in lives leveraging ETS.
“Ashley’s leadership has been instrumental in ETS’s growth,” says Matt Mackowski, Chairman, Managing Director, Telegraph Hill Partners & ETS Board Chairman
“Her deep industry knowledge and vision will keep us laser-focused on providing unparalleled solutions and support to our clients in the highly complex and costly areas of cell and gene therapy and transplant.”
As President, Hume will prioritize strengthening ETS’s ability to support clients navigating the complex landscape of high-cost therapies. This aligns with ETS’s commitment to help payers make informed pricing and risk management decisions regarding treatments for rare genetic diseases.
About Emerging Therapy Solutions
Emerging Therapy Solutions (ETS) helps reinsurance and stop-loss payers, health plans, and self-funded employers manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies. Learn more at [emergingtherapies.com](http://emergingtherapies.com).
